

Peptide · RT15
APX-3
APX-3 is Apex’s catalog name for a single-peptide research compound that engages GLP-1, GIP, and glucagon signaling—an approach sometimes informally described as “GLP-3.”
Search terminology: APX-3 is Apex’s catalog name for a triple-receptor research compound. It may also appear in searches as “GLP-3,” “RETA,” or “retatrutide.” “GLP-3” is an informal nickname, not an official scientific classification.
For laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent disease.
What researchers study
APX-3 in context
All three targets are class B G-protein-coupled receptors. APX-3 binding activates Gs-protein signaling, raises intracellular cyclic AMP, and produces different downstream effects depending on the receptor and tissue involved.
Read the full research profileReference profile
Identity & specifications
Reference identities are provided to clarify nomenclature. Salts, counterions, hydration, and analytical conventions can affect reported formula and mass. Consult the linked public record and your own laboratory methods.
Product questions
Before adding
to your bag.
What does the listed purity mean?
It is the catalog specification used to describe the intended material standard.
Is this material intended for human or veterinary use?
No. It is sold solely for lawful laboratory research and may not be consumed, self-administered, compounded for patient use, or used in humans or animals.
Does Apex provide preparation or dosing instructions?
No. Apex does not provide reconstitution, dosing, administration, treatment, or personal-use guidance.
Scientific context
Use evidence with precision.
What this profile does
It identifies the material and supplies neutral catalog details useful for research planning and recordkeeping.
What it does not do
It does not establish safety, efficacy, clinical suitability, or an expected human outcome. Preclinical observations cannot be presented as consumer benefits.


